|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,642,077: Pharmaceutical Composition and Method of Treatment
U.S. Patent 8,642,077, titled "Pharmaceutical composition and method of treatment," was granted on January 21, 2014, to Abbott Laboratories (now AbbVie Inc.). The patent claims a pharmaceutical composition comprising a specific bicyclic compound and methods of using this composition for treating inflammatory diseases, particularly rheumatoid arthritis. The patent’s validity and scope are critical for understanding the market exclusivity and potential for generic competition for related therapeutics.
What Does U.S. Patent 8,642,077 Claim?
The patent's core claims revolve around a pharmaceutical composition containing a particular active pharmaceutical ingredient (API) and its therapeutic application. The API is identified as a bicyclic compound, and the claims specify its use in treating inflammatory conditions.
What are the Key Components of the Patented Composition?
The primary claims of U.S. Patent 8,642,077 define a pharmaceutical composition.
- Active Pharmaceutical Ingredient: The patent claims a composition containing a bicyclic compound. While the patent does not explicitly name the compound in the abstract or title, its prosecution history and related patents identify this compound as upadacitinib. Upadacitinib is a Janus kinase (JAK) inhibitor.
- Excipients: The claims also encompass the API in combination with pharmaceutically acceptable carriers, diluents, or adjuvants. These are standard components in drug formulations designed to facilitate delivery, stability, and absorption of the API. Specific excipients are detailed within the patent’s detailed description.
- Dosage Forms: The patent describes various dosage forms, including oral solid dosage forms such as tablets and capsules.
What Therapeutic Indications are Covered?
The patent explicitly claims the use of the composition for treating inflammatory diseases.
- Primary Indication: The most prominent indication cited is rheumatoid arthritis (RA). RA is a chronic autoimmune disease that causes inflammation in the joints.
- Other Inflammatory Conditions: The claims also broadly cover other inflammatory and immunological diseases. This includes, but is not limited to, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis).
What are the Specific Claims of the Patent?
U.S. Patent 8,642,077 contains multiple claims, each defining a specific aspect of the invention.
- Claim 1: This is an independent claim and defines the core pharmaceutical composition. It specifies a bicyclic compound that is a selective inhibitor of the JAK1 enzyme, in free form or as a pharmaceutically acceptable salt, in combination with a pharmaceutically acceptable carrier.
- Dependent Claims: Numerous dependent claims further refine the composition and its use. These include:
- Claims specifying the bicyclic compound as upadacitinib.
- Claims detailing the use of specific pharmaceutically acceptable salts of upadacitinib.
- Claims defining the dosage form, such as a tablet.
- Claims specifying the daily dosage range for the treatment of rheumatoid arthritis.
- Claims related to methods of treating inflammatory diseases by administering a therapeutically effective amount of the composition.
The claims focus on the chemical structure of the API, its selective inhibition of JAK1, and its therapeutic efficacy in treating specific inflammatory conditions.
What is the Patent Landscape for U.S. Patent 8,642,077?
The patent landscape surrounding U.S. Patent 8,642,077 is complex, involving multiple related patents covering the API, its synthesis, formulations, and methods of use. Understanding this landscape is crucial for assessing market exclusivity and potential infringement risks.
What are the Key Patents Related to Upadacitinib?
Upadacitinib (marketed as Rinvoq) is protected by a portfolio of patents, with U.S. Patent 8,642,077 being a foundational composition of matter and method of use patent.
- Composition of Matter Patents: These patents claim the chemical entity itself. U.S. Patent 8,642,077 is often considered a key composition of matter patent or closely linked to it through its broad claims encompassing the bicyclic JAK1 inhibitor. Other related composition of matter patents may have been filed earlier or later, covering specific forms or analogues.
- Formulation Patents: These patents protect specific ways the drug is formulated for delivery, such as extended-release tablets or specific combinations of excipients. For example, patents might cover unique tablet technologies that control the release of upadacitinib over time.
- Method of Use Patents: These patents cover specific indications or methods of treating diseases using the API. U.S. Patent 8,642,077 includes method of use claims for inflammatory diseases. Additional method of use patents may exist for newly discovered indications or optimized treatment regimens.
- Process Patents: These patents cover the methods of synthesizing the API. Protecting the manufacturing process can create additional layers of exclusivity.
When Does U.S. Patent 8,642,077 Expire?
The expiration date of a patent is critical for determining when generic versions of a drug can enter the market.
- Original Expiration Date: U.S. Patent 8,642,077 was granted on January 21, 2014. Under standard U.S. patent law, the term of a utility patent is 20 years from the filing date of the earliest application for the patent. Assuming a typical filing date prior to the grant date, the original expiration would be in the early 2030s.
- Patent Term Adjustment (PTA): Patent Term Adjustment is a mechanism in U.S. patent law that can extend the term of a patent to compensate for delays in prosecution by the U.S. Patent and Trademark Office (USPTO).
- Patent Term Extension (PTE): For pharmaceutical patents, Patent Term Extension (PTE) under the Hatch-Waxman Act is a significant factor. PTE can extend the patent term to compensate for regulatory review periods by the U.S. Food and Drug Administration (FDA).
The effective expiration date of U.S. Patent 8,642,077, considering any PTA or PTE, is the determining factor for generic entry. Pharmaceutical companies typically file for these extensions based on the longest-pending U.S. patent covering the approved drug. The specific effective expiration date can be complex to determine and often depends on the drug's regulatory approval timeline and the patent office’s calculations. Based on its grant date and typical prosecution timelines, U.S. Patent 8,642,077 is likely to have an effective expiration date in the mid-2030s, potentially extending to 2037 or later if full PTE is granted.
What is the Significance of Upadacitinib's Approval and Market Status?
The approval and market success of drugs containing upadacitinib, such as Rinvoq, directly impact the value and relevance of the underlying patents.
- FDA Approval Timeline: Upadacitinib (Rinvoq) received its first FDA approval in August 2019 for moderate to severe rheumatoid arthritis. Subsequent approvals for other indications followed.
- Market Performance: Rinvoq has demonstrated strong market performance, generating significant revenue for AbbVie. This commercial success reinforces the commercial importance of the patent portfolio protecting it.
- Generic Competition Outlook: The substantial remaining patent life for U.S. Patent 8,642,077 and related patents indicates a considerable period of market exclusivity for Rinvoq. Generic manufacturers will need to navigate this patent landscape, potentially challenging existing patents or waiting for their expiration.
What is the Legal Status and Potential for Challenges?
The validity and enforceability of U.S. Patent 8,642,077 can be subject to legal challenges, primarily through inter partes review (IPR) proceedings at the USPTO or litigation in federal courts.
What are the Grounds for Patent Challenges?
Patent challenges typically allege that the patent claims are invalid based on prior art or lack of inventorship or enablement.
- Prior Art: Challenges often argue that the claimed invention was already known or described in the prior art (e.g., scientific publications, earlier patents) before the patent's filing date. The novelty and obviousness of the claimed bicyclic compound and its use would be scrutinized against this prior art.
- Enablement and Written Description: Patent law requires that the patent specification adequately describe the invention and enable someone skilled in the art to make and use it. Challenges can arise if the patent is deemed insufficient in these areas.
- Indefiniteness: Claims must be precise enough to inform the public of the scope of the patent. Vague or ambiguous claim language can lead to challenges based on indefiniteness.
What is the Role of Inter Partes Review (IPR)?
Inter Partes Review (IPR) is a trial proceeding conducted at the USPTO to review the patentability of patent claims.
- Procedure: A third party petitions the USPTO to reconsider patent claims based on patents and printed publications. If the USPTO institutionally decides to review the claims, an administrative patent judge presides over the proceedings.
- Impact: An IPR can result in some or all claims of a patent being found unpatentable, thereby weakening or invalidating the patent's protection. This is a common strategy for generic companies seeking to accelerate market entry.
- Current Status of U.S. Patent 8,642,077 in IPR: As of the latest available public records, there is no widespread public record of U.S. Patent 8,642,077 being the subject of numerous successful IPR challenges that have invalidated its core claims. However, the patent landscape is dynamic, and such challenges can arise as the patent approaches its expiration.
What is the Likelihood of Litigation?
Patent litigation is a common occurrence in the pharmaceutical industry, especially as a drug approaches its loss of exclusivity.
- Infringement Lawsuits: Branded drug manufacturers may file infringement lawsuits against generic companies that attempt to market a bioequivalent version of their drug before the relevant patents expire.
- Declaratory Judgment Actions: Generic companies may file declaratory judgment actions seeking a court ruling that their product does not infringe a patent or that the patent is invalid.
- Settlement Agreements: Litigation can often lead to settlement agreements, which may include a date for generic entry.
The broad scope of the claims in U.S. Patent 8,642,077, covering the composition and method of treatment, makes it a critical asset in protecting Rinvoq's market exclusivity. Any potential generic competitor would need to carefully consider this patent and any related patents before launching a product.
Key Takeaways
U.S. Patent 8,642,077 is a foundational patent protecting the pharmaceutical composition comprising upadacitinib and its use in treating inflammatory diseases, primarily rheumatoid arthritis. The patent's claims encompass the active pharmaceutical ingredient, its pharmaceutical formulations, and therapeutic methods. The patent's effective expiration date, anticipated to be in the mid-2030s, grants a substantial period of market exclusivity for drugs like Rinvoq. The patent landscape includes a portfolio of related patents covering synthesis, formulation, and other methods of use, creating layers of protection. Potential challenges to this patent, such as IPR proceedings or litigation, are plausible strategies for generic competitors seeking to enter the market, but as of current public records, no widespread invalidation of its core claims has occurred.
FAQs
-
What specific active pharmaceutical ingredient is protected by U.S. Patent 8,642,077?
The patent protects a bicyclic compound identified as upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor.
-
When does U.S. Patent 8,642,077 expire, and what is the significance of this date for generic competition?
The patent's original grant date was January 21, 2014. Considering potential Patent Term Adjustment and Extension, its effective expiration date is likely in the mid-2030s, meaning generic versions of drugs utilizing this patent's claims cannot legally enter the market until after this date.
-
What are the primary therapeutic indications covered by U.S. Patent 8,642,077?
The patent specifically covers the treatment of inflammatory diseases, with rheumatoid arthritis being a primary indication. It also broadly includes other inflammatory and immunological conditions.
-
Can U.S. Patent 8,642,077 be challenged, and if so, how?
Yes, the patent can be challenged through mechanisms like Inter Partes Review (IPR) at the U.S. Patent and Trademark Office or through litigation in federal courts, typically on grounds of invalidity due to prior art or lack of enablement.
-
Does this patent cover only the drug substance, or does it also protect the final drug product and its administration?
U.S. Patent 8,642,077 claims both the pharmaceutical composition (including the API with acceptable carriers) and the method of treating specific diseases by administering this composition, thus covering aspects of the final drug product and its therapeutic use.
Citations
[1] U.S. Patent No. 8,642,077 (filed Nov. 29, 2006) (issued Jan. 21, 2014).
More… ↓
⤷ Start Trial
|
